Most stock stories have a dozen moving parts. This one is simple. A government gives this company a score. Pass, and it gets paid a bonus on a contract covering millions of people. Fail, and it gets nothing. 

Stay with this, and you will see why the stock is undervalued and why it fell apart in the first place.

Asset Management

Rithm Capital Corp. (NYSE: RITM) is bringing institutional capital into its commercial real estate portfolio through a new joint venture with DRA Advisors. The partnership covers 1301 Avenue of the Americas, a fully leased, 1.7-million-square-foot Manhattan office tower.

Rithm retains majority ownership and will continue operating the property through Elecor Properties. Near $8.80, the stock trades at roughly 0.7 times its $12.33 book value and about 4 times forward earnings, while its $1 annual dividend yields above 11%.

The arrangement supports Rithm’s effort to expand beyond its traditional mortgage business into alternative asset management. When measuring the discount, you now have evidence that an outside institution will commit capital to a major property while leaving Rithm in control of operations.

Institutional Capital Can Stretch Rithm’s Balance Sheet

DRA manages $13.8 billion in gross assets, giving the partnership more weight than an internal property transfer. Similar transactions across Elecor’s portfolio could release capital, reduce the amount Rithm must commit to individual buildings, and create recurring management income without surrendering every ownership benefit.

Office Exposure Still Carries Real Risk

The companies did not disclose the financial terms, and commercial property values remain vulnerable to high borrowing costs and weaker leasing conditions. Rithm also carries a complex balance sheet that can move sharply with credit markets.

Still, the fully leased building, 2.4 times dividend coverage, and outside validation deserve a place in your assessment of whether the current book-value discount is excessive.

Vacation Ownership

Hilton Grand Vacations Inc. (NYSE: HGV) opened Ka Haku, a Hilton Club, in Waikiki today, adding 205 suites. It is the company’s first Hilton Club-branded property in Hawaii and its 14th resort in the state.

Around $34, Hilton Grand Vacations carries a market value near $3.6 billion. Its roughly $11 billion enterprise value equals less than 9 times management’s 2026 adjusted EBITDA guidance of $1.225 billion to $1.265 billion, while the shares remain below earlier analyst targets.

Ka Haku adds more than rooms. Vacation-ownership properties can produce contract sales, financing income, and recurring management fees. The opening makes the discount easier to test because you can compare sales at a new premium resort against the integration problems weighing on older Bluegreen locations.

Hawaii Adds Higher-Value Inventory

Hilton Grand Vacations already serves more than 720,000 club members, giving Ka Haku an existing customer base rather than requiring demand to start from zero. Its Waikiki location, premium positioning, and exclusive owner amenities can support higher-value sales while expanding inventory in a market where the brand already has recognition.

Debt Leaves Little Room for Weak Execution

Hilton Grand Vacations carries approximately $7.9 billion of debt, and tighter consumer financing can slow vacation-ownership sales. Bluegreen integration also remains unfinished after weaker sales execution at some locations.

Still, second-quarter free-cash-flow margin improved to 13.3%, management maintained its EBITDA guidance, and the new resort adds capacity, giving your valuation work another important factor to consider at the current multiple.

Biotechnology

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) reported five-year Phase 3 extension data today for POMBILITI and OPFOLDA in adults with late-onset Pompe disease. The 82-patient study showed durable walking performance, stable lung function, and no new safety concerns.

The stock trades near 13 times forward earnings, roughly one-third below the biotechnology industry median, while free-cash-flow yield sits above 6%. BioMarin also entered the period with stronger operating momentum after second-quarter revenue rose 20% to $990 million and adjusted earnings exceeded expectations.

POMBILITI and OPFOLDA came through BioMarin’s $4.8 billion acquisition of Amicus Therapeutics. Five years of follow-up lets you judge the acquired franchise on durable patient outcomes rather than a brief clinical window, while management estimates approximately $1.2 billion in potential peak sales.

A Broader Earnings Base Is Taking Shape

BioMarin expects GALAFOLD and the Pompe therapy to produce a non-GAAP operating margin above 60% by 2030. Combined with continued growth from VOXZOGO, the acquired drugs can broaden revenue beyond the company’s existing rare-disease portfolio, reduce dependence on any single growth driver, and support faster earnings growth if integration proceeds as planned.

Debt Cannot Be Ignored

The Amicus transaction added about $3.7 billion of debt, leaving BioMarin dependent on steady cash generation and disciplined execution. Competition, integration problems, or slower adoption would weaken the margin target.

Until leverage moves toward management’s goal of less than 2.5 times by mid-2027, the five-year clinical evidence should inform your risk limits rather than erase them.

Group 1 Automotive (NYSE: GPI)

Group 1 runs car dealerships across the United States and the United Kingdom. Here is the part most people get wrong: dealerships do not really make their money selling cars. The margin lives in financing, insurance products, servicing, and parts, which is why the service bays keep humming regardless of what new vehicle demand does.

The stock trades roughly 40% below its GF Value estimate, and investment firm Conifer Management has bought about $187.3 million of stock through open market purchases over the past twelve months.

That is an unusual amount of conviction in one place, though it is one firm building a position rather than the entire management team, and some senior executives did sell shares in August. Third quarter earnings land October 28. The earnings multiple sits higher than the discount alone implies, so this rests on the fair value model rather than the profit line.

Humana (NYSE: HUM)

Humana sells Medicare Advantage plans, the privately run alternative to government Medicare that older Americans can choose instead. Its profitability hangs almost entirely on a government star ratings system, because highly rated plans collect bonus payments and poorly rated ones simply do not. That is why the stock fell apart when ratings slipped, and it is why everything now hinges on one date.

New ratings are due around October 8, with the key question being whether its H5216 contract, covering roughly 2.4 million members, climbs back to bonus level. Barclays upgraded the stock in late September betting precisely that.

Third quarter earnings follow in early November, where management should show whether the pricing reset is doing its job. This leans binary, so size it knowing a disappointing ratings day genuinely hurts.

Kratos Defense (NASDAQ: KTOS)

Kratos builds unmanned aircraft and missile systems, including cheap drones designed to fly alongside crewed fighter jets and absorb the risk a pilot otherwise would. On September 21, it successfully ignited the GEK800 cruise missile engine developed with GE Aerospace, which de-risks a key propulsion milestone on a program the market had been nervous about.

The shares have fallen sharply over the past year, and Jefferies kept its Buy rating on September 30 while trimming its target to $68 on a softer cash flow outlook. Defense budgets are not shrinking, and low-cost strike is exactly where spending is headed.

Production is the harder hurdle though, and a successful test is not the same as a working factory. That is what the next quarterly update needs to address.

That's our coverage for today; thanks for reading! Reply to this email with feedback or any stocks you want me to check out.

Best Regards,
—Noah Zelvis
Undervalued Edge